Compare Align Technology, Inc. (ALGN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Align Technology, Inc. trades at $172.77 (market cap $12.29B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B). The key difference: Align Technology, Inc. is far larger — about 6.8× Recursion Pharmaceuticals Inc's market cap, and Align Technology, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ALGN | RXRX | |
|---|---|---|
Market Cap | $12.29B | $1.81B |
Sector | Health | Health |
52-Week High | $197.51 | $6.79 |
52-Week Low | $124.88 | $2.84 |
Enterprise Value | $11.30B | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
